2023
Continuous Glucose Monitoring Provides Durable Glycemic Benefit in Adolescents and Young Adults with Type 1 Diabetes: 12‐Month Follow‐Up Results
Miller K, Bauza C, Kanapka L, Clements M, DeSalvo D, Hood K, Messer L, Sherr J, Bergamo K, Criego A, Freiner E, Lyons S, Monzavi R, Moore W, Prahalad P, Simmons J, Sulik M, Wadwa R, Weinstock R, Willi S, Williams K, Laffel L, Group F. Continuous Glucose Monitoring Provides Durable Glycemic Benefit in Adolescents and Young Adults with Type 1 Diabetes: 12‐Month Follow‐Up Results. Pediatric Diabetes 2023, 2023: 6718115. PMID: 40303270, PMCID: PMC12016685, DOI: 10.1155/2023/6718115.Peer-Reviewed Original ResearchType 1 diabetesMedian percent timeUse of CGMBlood glucose monitoringYoung adultsCGM initiationExtension phaseGlucose monitoringPercent timeContinuous glucose monitoringMean hemoglobinGlycemic controlCGM groupUp ResultsClinical trialsGlycemic outcomesGlycemic benefitsCGM useMonitoring interventionsType 1Further evaluationBGM groupWeeksDlAdultsTriglyceride Clearance in Hypertriglyceridemic Pancreatitis: Time Course and Its Implications for Management
Majumdar S. Triglyceride Clearance in Hypertriglyceridemic Pancreatitis: Time Course and Its Implications for Management. Endocrine Practice 2023, 29: 971-979. PMID: 37714331, DOI: 10.1016/j.eprac.2023.09.002.Peer-Reviewed Original ResearchInitial TG levelsTG levelsInsulin therapyMedical record reviewDiagnosis of pancreatitisTime courseHypertriglyceridemic pancreatitisIntravenous insulinRecord reviewTime-course evaluationTriglyceride clearanceInsulin treatmentNutritional intakeSeparate patientsTG loweringDlPatientsLonger durationPancreatitisShort durationHTGTherapyCauseClearanceDays
2022
Pulmonary and physical function limitations in aging men with and without HIV from the Multicenter AIDS Cohort Study (MACS)
Abdo M, Kunisaki K, Morris A, Stosor V, Chang D, D'Souza G, Crothers K, Abdel-Maksoud M, DiGuiseppi C, Brown T, MaWhinney S, Erlandson K. Pulmonary and physical function limitations in aging men with and without HIV from the Multicenter AIDS Cohort Study (MACS). Annals Of Epidemiology 2022, 76: 50-60. PMID: 36244514, PMCID: PMC9881119, DOI: 10.1016/j.annepidem.2022.10.005.Peer-Reviewed Original ResearchConceptsMulticenter AIDS Cohort StudyWeak grip strengthGait speedGrip strengthPhysical functionPulmonary impairmentPulmonary functionGreater oddsSimilar gait speedSlow gait speedPhysical function limitationsAIDS Cohort StudyCohort study dataNormal FEVCohort studyMedian ageHIV serostatusHIVFunction limitationsFEVDlPhysical outcomesAgeFrailtyMenSafety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial
Sherr JL, Bode BW, Forlenza GP, Laffel LM, Schoelwer MJ, Buckingham BA, Criego AB, DeSalvo DJ, MacLeish SA, Hansen DW, Ly TT, Sherr J, Weyman K, Tichy E, VanName M, Brei M, Zgorski M, Steffen A, Carria L, Bode B, Busby A, Forlenza G, Wadwa R, Slover R, Cobry E, Messer L, Laffel L, Isganaitis E, Ambler-Osborn L, Freiner E, Turcotte C, Volkening L, Schoelwer M, Brown S, Krauthause K, Emory E, Oliveri M, Buckingham B, Ekhlaspour L, Kingman R, Criego A, Schwartz B, Gandrud L, Grieme A, Hyatt J, DeSalvo D, McKay S, DeLaO K, Villegas C, MacLeish S, Wood J, Kaminski B, Casey T, Campbell W, Behm K, Adams R, Hansen D, Stone S, Bzdick S, Bulger J, Agostini L, Doolittle S, Kivilaid K, Kleve K, Ly T, Dumais B, Vienneau T, Huyett L, Lee J, O’Connor J, Benjamin E. Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial. Diabetes Care 2022, 45: 1907-1910. PMID: 35678724, PMCID: PMC9346983, DOI: 10.2337/dc21-2359.Peer-Reviewed Original ResearchConceptsInsulin delivery systemsSingle-arm studyLong-term complicationsMulticenter clinical trialType 1 diabetesSensor glucose levelsYoung childrenBaseline data collectionReduced hypoglycemiaDiabetic ketoacidosisGlycemic targetsUsual therapyGlycemic measuresSevere hypoglycemiaDelivery systemStudy endGlycemic outcomesClinical trialsGlucose levelsType 1HypoglycemiaInvestigational systemDlChildrenStudy phaseRelationship Between Glucose Time in Range in Diabetic and Non-Diabetic Patients and Mortality in Critically Ill Patients
Ammar MA, Ammar AA, Wee T, Deshpande R, Band M, Akhtar S. Relationship Between Glucose Time in Range in Diabetic and Non-Diabetic Patients and Mortality in Critically Ill Patients. Journal Of Intensive Care Medicine 2022, 37: 1625-1633. PMID: 35491687, DOI: 10.1177/08850666221098383.Peer-Reviewed Original ResearchConceptsNon-diabetic patientsBlood glucose rangeDiabetic patientsIll patientsGlucose rangeTIR 70Hospital mortalityMortality rateHospital mortality rateNon-diabetic cohortLower mortality rateAdult patientsCohort studyMortality benefitSingle centerGlucose timePercentage of timeHigh incidencePatientsMortalityDlLtDiabeticsICUHyperglycemia
2021
Alcohol-related deaths among young passengers: An analysis of national alcohol-related fatal crashes
Romano E, Fell J, Li K, Simons-Morton BG, Vaca FE. Alcohol-related deaths among young passengers: An analysis of national alcohol-related fatal crashes. Journal Of Safety Research 2021, 79: 376-382. PMID: 34848017, PMCID: PMC8640369, DOI: 10.1016/j.jsr.2021.10.004.Peer-Reviewed Original ResearchConceptsBlood alcohol concentrationHigh blood alcohol concentrationsAlcohol-related deathsMotor vehicle deathsRace/ethnicityDrivers 15Fatality Analysis Reporting SystemAlcohol-related fatal crashesAlcohol-related fatalitiesHigh prevalenceHigh-risk situationsSecondary analysisYoung passengersWeekday nightsUnderage drinking driversImpaired driversPublic healthDrinking driversReporting systemDlWeekend nightsFatalitiesDeathAlcohol concentrationFatal crashesExtended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes.
Kanapka LG, Wadwa RP, Breton MD, Ruedy KJ, Ekhlaspour L, Forlenza GP, Cengiz E, Schoelwer MJ, Jost E, Carria L, Emory E, Hsu LJ, Weinzimer SA, DeBoer MD, Buckingham BA, Oliveri M, Kollman C, Dokken BB, Cherñavvsky D, Beck RW. Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes. Diabetes Care 2021, 44: 473-478. PMID: 33355258, PMCID: PMC7818334, DOI: 10.2337/dc20-1729.Peer-Reviewed Original ResearchConceptsType 1 diabetesChildren 6Sensor-Augmented Pump TherapyWeeks of useDiabetic ketoacidosisDays of useGlycemic controlSAP groupSevere hypoglycemiaPump therapyClinical trialsPercentage of timeCLC groupMean TIRDiabetesFurther evaluationCohortRCTsDlWeeksChildrenDaysExtended useParticipantsKetoacidosis
2020
Association of decreasing hemoglobin levels with the incidence of acute kidney injury after percutaneous coronary intervention: a prospective multi-center study
Kuno T, Numasawa Y, Mikami T, Niimi N, Sawano M, Kodaira M, Suzuki M, Ueno K, Ueda I, Fukuda K, Kohsaka S. Association of decreasing hemoglobin levels with the incidence of acute kidney injury after percutaneous coronary intervention: a prospective multi-center study. Heart And Vessels 2020, 36: 330-336. PMID: 33034713, DOI: 10.1007/s00380-020-01706-w.Peer-Reviewed Original ResearchConceptsAcute kidney injuryPercutaneous coronary interventionRisk of AKIHemoglobin dropAKI incidenceKidney injuryCoronary interventionHemoglobin levelsProspective multi-center studySerum creatinine levelsMulti-center studyRelative decreaseConsecutive patientsCreatinine levelsIndependent predictorsRisk factorsHemoglobin changeHigh riskAbsolute decreaseLogistic regressionPatientsIncidenceHemoglobinInjuryDl1296-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Children Aged 2-12 Years without Increasing Risk of Hypoglycemia
SHERR J, BUCKINGHAM B, FORLENZA G, GALDERISI A, EKHLASPOUR L, WADWA R, ZGORSKI M, KINGMAN R, BERGET C, LEE J, OCONNOR J, DUMAIS B, VIENNEAU T, HUYETT L, LY T. 1296-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Children Aged 2-12 Years without Increasing Risk of Hypoglycemia. Diabetes 2020, 69 DOI: 10.2337/db20-1296-p.Peer-Reviewed Original ResearchDiabetes careGlucose targetsEli LillySerious adverse eventsHigh-fat mealRisk of hypoglycemiaAdvisory PanelType 1 diabetesChildren Aged 2MannKind CorporationHybrid closed-loop systemT1D durationAdverse eventsT1D ExchangeFat mealGlucose managementMean glucosePivotal studiesAged 2Bolus challengeDaily exerciseInvestigational deviceDlPercent timeTarget glucose978-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Adults and Adolescents without Increasing Risk of Hypoglycemia
FORLENZA G, BUCKINGHAM B, SHERR J, WADWA R, GALDERISI A, EKHLASPOUR L, BERGET C, HSU L, ZGORSKI M, LEE J, OCONNOR J, DUMAIS B, VIENNEAU T, HUYETT L, LY T. 978-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Adults and Adolescents without Increasing Risk of Hypoglycemia. Diabetes 2020, 69 DOI: 10.2337/db20-978-p.Peer-Reviewed Original ResearchDiabetes careMeal bolusEli LillyPercent timeRisk of hypoglycemiaAdvisory PanelType 1 diabetesHigh-fat dinnerMannKind CorporationHybrid closed-loop systemT1D durationGlucose targetsT1D ExchangeGlucose managementPivotal studiesDaily exerciseInvestigational deviceDlTarget glucoseCareLexicon PharmaceuticalsMedtronicBolusLower targetsAdults
2019
Brief Report: Zinc Supplementation and Inflammation in Treated HIV.
Dirajlal-Fargo S, Yu J, Kulkarni M, Sattar A, Funderburg N, Barkoukis H, Mccomsey G. Brief Report: Zinc Supplementation and Inflammation in Treated HIV. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2019, 82: 275-280. PMID: 31609926, PMCID: PMC6812547, DOI: 10.1097/qai.0000000000002129.Peer-Reviewed Original ResearchConceptsZinc supplementationZinc levelsDouble-arm studyHigh-dose armLow-dose armMedian zinc levelStable antiretroviral therapyMarkers of inflammationYears old peopleTreated HIVAntiretroviral therapyHIV infectionMedian ageClinical comorbiditiesBiomarker levelsMonocyte activationLarge effect sizesHIVInflammationPilot studyPhase ISupplementationDlElemental zincAfrican AmericansSafety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions
Sherr J, Buckingham BA, Forlenza G, Galderisi A, Ekhlaspour L, Wadwa RP, Carria L, Hsu L, Berget C, Peyser TA, Lee JB, O'Connor J, Dumais B, Huyett L, Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. Diabetes Technology & Therapeutics 2019, 22: 174-184. PMID: 31596130, PMCID: PMC7047109, DOI: 10.1089/dia.2019.0286.Peer-Reviewed Original ResearchConceptsDaily physical activityPhysical activityFree-living conditionsPercentage timeMultiple daily injectionsType 1 diabetesRespective age groupsCohort of participantsHybrid closed-loop systemPrimary endpointDaily injectionsEligible participantsClosed-loop studiesPercentage of timeTherapy phaseInvestigational deviceNights of useAge groupsSensor glucoseType 1Home settingDlSignificant decreaseUsual routineAdultsFeasibility Studies of an Insulin-Only Bionic Pancreas in a Home-Use Setting
Ekhlaspour L, Nally LM, El-Khatib FH, Ly TT, Clinton P, Frank E, Tanenbaum ML, Hanes SJ, Selagamsetty RR, Hood K, Damiano ER, Buckingham BA. Feasibility Studies of an Insulin-Only Bionic Pancreas in a Home-Use Setting. Journal Of Diabetes Science And Technology 2019, 13: 1001-1007. PMID: 31470740, PMCID: PMC6835195, DOI: 10.1177/1932296819872225.Peer-Reviewed Original ResearchConceptsUsual care armStudy armsOpen-label non-randomized studyHome-use settingDaily insulin doseNon-randomized studiesCare armUsual careInsulin doseIncreased riskMean ageDiabetes burdenGlycemic outcomesHypoglycemic riskIntervention periodAverage glucoseBody weightConsecutive weeksBionic pancreasDynamic glucoseSignificant differencesDlInsulinFactor testingRiskComparing different assessments of remnant lipoprotein cholesterol: The very large database of lipids
Faridi KF, Quispe R, Martin SS, Hendrani AD, Joshi PH, Brinton EA, Cruz DE, Banach M, Toth PP, Kulkarni K, Jones SR. Comparing different assessments of remnant lipoprotein cholesterol: The very large database of lipids. Journal Of Clinical Lipidology 2019, 13: 634-644. PMID: 31320236, DOI: 10.1016/j.jacl.2019.06.001.Peer-Reviewed Original ResearchConceptsLow-density lipoprotein cholesterolRemnant lipoprotein cholesterolLipoprotein cholesterolLipid parametersVertical auto profile ultracentrifugationRLP-C levelsAtherosclerotic cardiovascular diseaseLipid panelMedian ageHighest quintileRisk factorsCardiovascular diseaseSecond quintileFriedewald equationCholesterolQuintileDlRLPParameters correlatesSubject differencesLipidsCohortDisease
2018
Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Adolescents with Type 1 Diabetes over Five Days Under Free-Living Conditions
FORLENZA G, BUCKINGHAM B, SHERR J, PEYSER T, LEE J, OCONNOR J, DUMAIS B, HUYETT L, LAYNE J, LY T. Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Adolescents with Type 1 Diabetes over Five Days Under Free-Living Conditions. Diabetes 2018, 67 DOI: 10.2337/db18-1376-p.Peer-Reviewed Original ResearchModerate-intensity exerciseDiabetes careGlycemic outcomesFree-living conditionsType 1 diabetesMin/dAdvisory PanelHybrid closed-loop systemStandard therapyDays of useEligible participantsAge 14.3Percentage of timeCGM useInvestigational deviceMedtronic MiniMedType 1DlTime 70Usual routineCareEli LillyOmnipodAdolescentsConcomitant reductionSafety and Performance of the Omnipod® Hybrid Closed-Loop System in Children Aged 6-12 Years with Type 1 Diabetes over Five Days Under Free-Living Conditions
SHERR J, FORLENZA G, BUCKINGHAM B, PEYSER T, LEE J, OCONNOR J, DUMAIS B, HUYETT L, LAYNE J, LY T. Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Children Aged 6-12 Years with Type 1 Diabetes over Five Days Under Free-Living Conditions. Diabetes 2018, 67 DOI: 10.2337/db18-1377-p.Peer-Reviewed Original ResearchModerate-intensity exerciseDiabetes careGlycemic outcomesFree-living conditionsType 1 diabetesChildren Aged 6Min/dAdvisory PanelAge 9.9Hybrid closed-loop systemStandard therapyDays of useEligible participantsPercentage of timeCGM useAged 6Investigational deviceMedtronic MiniMedType 1DlTime 70Usual routineCareEli LillyOmnipodSafety and Performance of the Omnipod® Hybrid Closed-Loop System in Adults with Type 1 Diabetes over Five Days Under Free-Living Conditions
BUCKINGHAM B, SHERR J, FORLENZA G, PEYSER T, LEE J, OCONNOR J, DUMAIS B, HUYETT L, LAYNE J, LY T. Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Adults with Type 1 Diabetes over Five Days Under Free-Living Conditions. Diabetes 2018, 67 DOI: 10.2337/db18-207-or.Peer-Reviewed Original ResearchModerate-intensity exerciseDiabetes careGlycemic outcomesFree-living conditionsType 1 diabetesMin/dAdvisory PanelHybrid closed-loop systemStandard therapyDays of useEligible participantsPercentage of timeCGM useInvestigational deviceMedtronic MiniMedType 1DlTime 70Usual routineCareEli LillyOmnipodAdultsConcomitant reductionDays
2015
Do you see what I see? A randomised pilot study to evaluate the effectiveness and efficiency of simulation-based training with videolaryngoscopy for neonatal intubation
Johnston LC, Chen R, Whitfill TM, Bruno CJ, Levit OL, Auerbach MA. Do you see what I see? A randomised pilot study to evaluate the effectiveness and efficiency of simulation-based training with videolaryngoscopy for neonatal intubation. BMJ Simulation & Technology Enhanced Learning 2015, 1: 12. PMID: 35517843, PMCID: PMC8936656, DOI: 10.1136/bmjstel-2015-000031.Peer-Reviewed Original ResearchAirway viewMinimum passing scorePilot studyAirway gradeBaseline demographicsDuration of attemptsPatient's airwayAirway intubationNeonatal intubationNeonatal resuscitationGlobal skills assessmentStorz C-MACDuration of trainingEducational sessionsVideolaryngoscopyAirwayDlSmall sample sizeEducational interventionIntubation trainingAirway trainersDirect visual confirmationIntubationC-MACSignificant differencesThe Utility of Inpatient Rebound Bilirubin Levels in Infants Readmitted After Birth Hospitalization for Hyperbilirubinemia
Berkwitt A, Osborn R, Grossman M. The Utility of Inpatient Rebound Bilirubin Levels in Infants Readmitted After Birth Hospitalization for Hyperbilirubinemia. Hospital Pediatrics 2015, 5: 74-78. PMID: 25646199, DOI: 10.1542/hpeds.2014-0074.Peer-Reviewed Original ResearchConceptsBilirubin levelsLength of stayBirth hospitalizationIndirect hyperbilirubinemiaRebound groupDiscontinuation of phototherapyRetrospective cohort studyManagement of infantsCharacteristics of childrenCohort studySecondary outcomesHospital readmissionPrimary outcomePatient populationSubgroup analysisClinical utilityPatientsInfantsHospitalizationHyperbilirubinemiaPhototherapyReadmissionStayDlPresent study
2014
Utilization of Exploration-Based Learning and Video-Assisted Learning to Teach GlideScope Videolaryngoscopy
Johnston LC, Auerbach M, Kappus L, Emerson B, Zigmont J, Sudikoff SN. Utilization of Exploration-Based Learning and Video-Assisted Learning to Teach GlideScope Videolaryngoscopy. Teaching And Learning In Medicine 2014, 26: 285-291. PMID: 25010241, DOI: 10.1080/10401334.2014.910462.Peer-Reviewed Original ResearchConceptsEndotracheal intubationPediatric critical carePediatric endotracheal intubationSuccessful endotracheal intubationProcedural performancePediatric emergency medicinePediatric airwayProcedural durationGlideScope videolaryngoscopyAirway simulatorCritical carePediatric providersPediatric anesthesiaIntubation procedureAdult airwayGlideScopeDlRandom orderPediatric residentsEmergency medicineLevel of trainingAirway trainersSuccess rateAirwayBaseline success rate
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply